Skip to main content

Advertisement

SpringerLink
Log in

The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials

  • Review Article
  • Published:
Updates in Surgery Aims and scope Submit manuscript

Abstract

To evaluate the short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the patients with advanced gastric cancer (AGC) through randomized controlled trials (RCTs). We analyzed the endpoints of AGC patients including 1-, 2-, 3-, and 5-year overall survival (OS), intestinal anastomotic leakage, myelosuppression, nausea and vomiting from included studies. And we retrieved RCTs from medical literature databases. Risk ratios (RR) was used to calculated the endpoints. Totally, we retrieved 13 articles (14 trial comparisons) which contained 1091 patients. They were randomized to HIPEC group and control group. The results showed that there was no significant differences in survival rates between HIPEC group and control group at 1-, 2- and 3-year follow-up, while a statistical significant overall survival effect was found at the 5-year follow-up [RR: 1.20, 95% CI 1.01 to 1.43, I2 = 0.0%]. And there is no significant difference in the risk of intestinal anastomotic leakage, myelosuppression and nausea and vomiting. Compared with the control group, HIPEC could improve the long-term OS without increasing the risk of adverse effect in AGC patients with/without peritoneal carcinomatosis, but there was no benefit at short-term OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The author could be contacted for data requests.

References

  1. Correa P (2013) Gastric cancer: overview. Gastroenterol Clin N Am 42:211–217

    Article  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209–249

    Google Scholar 

  3. Chen WQ, Li H, Sun KX et al (2018) Report of cancer incidence and mortality in China, 2014 Zhonghua zhong liu za zhi. Chin J Oncol 40(1):5–13

    CAS  Google Scholar 

  4. Fujitani K (2013) Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 30(2):119–129

    Article  CAS  PubMed  Google Scholar 

  5. Yarema R, Mielko J, Fetsych T et al (2019) Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitoneally disseminated gastric cancer: a retrospective cooperative central-Eastern European study. Cancer Med 45:144

    Article  Google Scholar 

  6. Zheng GZ, Rui T, Min Y et al (2006) Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study Dig Surg 23(1–2):93–102

    Google Scholar 

  7. Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Can Res 40(2):256–260

    CAS  Google Scholar 

  8. Mar A, Jpm B, Rb C et al (2020) A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 244:101–105

    Article  Google Scholar 

  9. Klaver C, Wisselink DD, Punt C et al (2019) Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4(10):761–770

    Article  PubMed  Google Scholar 

  10. Cortés-Guiral D, Mohamed F, Glehen O et al (2020) "Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Eur J Surg Oncol 47(1):60–64

    Article  PubMed  Google Scholar 

  11. Dahdaleh FS, Turaga KK (2018) Evolving treatment strategies and outcomes in advanced gastric cancer with peritoneal metastasis. Surg Oncol Clin N Am 27(3):519–537

    Article  PubMed  Google Scholar 

  12. Beeharry MK, Zhu ZL, Liu WT et al (2019) Correction to: Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer 19(1):1–3

    Google Scholar 

  13. Golse N, Bakrin N, Passot G et al (2012) Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 106(2):197–203

    Article  PubMed  Google Scholar 

  14. Sugarbaker PH (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 48:42–49

    Article  PubMed  Google Scholar 

  15. Page MJ, Mckenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):1–11

    Article  Google Scholar 

  16. Higgins JPT, Altman DG, Gtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

  17. Koga S, Hamazoe R, Maeta M et al (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237

    Article  CAS  PubMed  Google Scholar 

  18. Kaibara N, Hamazoe R, Iitsuka Y et al (1989) Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 36(2):75–78

    CAS  PubMed  Google Scholar 

  19. Hamazoe R, Maeta M, Kaibara N (2015) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73(8):2048–2052

    Article  Google Scholar 

  20. Fujimura T, Yonemura Y, Muraoka K et al (1994) Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 18(1):150

    Article  CAS  PubMed  Google Scholar 

  21. Ikeguchi M, Kondou A, Oka A et al (1995) Effect of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 161(8):581–586

    CAS  PubMed  Google Scholar 

  22. Fujimoto S, Takahashi M, Mutou T et al (2015) Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85(3):529–534

    Article  Google Scholar 

  23. Yonemura Y, Aretxabala XD, Fujimura T et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48(42):1776–1782

    CAS  PubMed  Google Scholar 

  24. Yang XJ, Huang CQ, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cui H, Ge H, Bai X et al (2014) Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med 7(5):1083–1088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Huang O, Lu XH, Xu XD et al (2015) Fibrin-sealant-delivered cisplatin chemotherapy versus cisplatin hyperthermic intraperitoneal perfusion chemotherapy for locally advanced gastric cancer without peritoneal metastases: a randomized phase-ii clinical trial with a 40-month follow-up. Cell Biochem Biophys 71(2):1171–1180

    Article  CAS  PubMed  Google Scholar 

  27. Rudloff U, Langan RC, Mullinax JE et al (2014) Impact of maximal cytoreductive surgery plus regional heated intra-peritoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 110(3):275–284

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lu C, Li L, Luo Z et al (2016) Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. Neoplasma 63:299–303

    CAS  PubMed  Google Scholar 

  29. Fan B, Bu Z, Zhang J et al (2021) Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer 21(1):216

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sterne J, Savovi J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Clin Res 366:l4898

    Google Scholar 

  31. Afsar B, Kanbay M (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362

    Article  PubMed  Google Scholar 

  32. Nissan A, Garofalo A, Esquivel J (2010) Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: why haven’t we reached the promised land? J Surg Oncol 102(5):359–360

    Article  PubMed  Google Scholar 

  33. Reutovich MY, Krasko OV, Sukonko OG (2021) Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol 12(Suppl 1):S5–S17

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ji Z, Zhang Y, Li Y (2021) Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review. J Gastrointest Oncol 12(1):S70–S78

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pallas N, Karamveri C, Kyziridis D et al (2017) Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis. J BUON: Off J Balk Union Oncol 22(6):1547–1553

    Google Scholar 

  36. Di N, Liu F et al (2009) Destruction of gastric cancer cells to mesothelial cells by apoptosis in the early peritoneal metastasis. J Huazhong Univ Sci Technol Med Sci 29:163–168

    Article  Google Scholar 

  37. Liu G, Huang JP (2011) The clinical analysis of laparoscopic assisted D_2 radical gastrectomy for progressed gastric carcinoma. Chin J Mod Op Surg 15(5):355-357

  38. Desiderio J, Chao J, Melstrom L et al (2017) The thirty-year experience - a meta-analysis of randomized and high-quality non-randomized studies of hyperthermic intraperitoneal chemotherapy(HIPEC) in the treatment of gastric cancer. Eur J Cancer 79:1–14

    Article  PubMed  PubMed Central  Google Scholar 

  39. Liu Y-W, Ying Du et al (2019) Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials. J Int Med Res 47(12):5926–5936

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Huachu Deng and Baibei Li contributed equally to this work.

Authors and Affiliations

  1. Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Huachu Deng & Xingan Qin

  2. Department of Hepatobiliary, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Baibei Li

Authors
  1. Huachu Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baibei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xingan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xingan Qin.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

13304_2022_1376_MOESM1_ESM.tif

Supplementary file1 Forest plot of the risk of intestinal anastomotic leakage in HIPEC group and the Control group. HIPEC hyperthermic intraperitoneal chemotherapy (TIF 1446 KB)

13304_2022_1376_MOESM2_ESM.tif

Supplementary file2 Forest plot of the risk of myelosuppression in HIPEC group and the Control group. HIPEC hyperthermic intraperitoneal chemotherapy (TIF 1462 KB)

13304_2022_1376_MOESM3_ESM.tif

Supplementary file3 Forest plot of the risk of nausea and vomiting in HIPEC group and the Control group. HIPEC hyperthermic intraperitoneal chemotherapy (TIF 1512 KB)

13304_2022_1376_MOESM4_ESM.tif

Supplementary file4 Funnel plot of OS at 1 year follow-up. RR= Risk Ratio, HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival (TIF 475 KB)

13304_2022_1376_MOESM5_ESM.tif

Supplementary file5 Funnel plot of OS at 3 years follow-up. RR Risk Ratio, HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival (TIF 475 KB)

13304_2022_1376_MOESM6_ESM.tif

Supplementary file6 Sensitivity analysis of OS at 1 year follow-up. HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival (TIF 442 KB)

13304_2022_1376_MOESM7_ESM.tif

Supplementary file7 Sensitivity analysis of OS at 2 years follow-up. HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival(TIF 442 KB)

13304_2022_1376_MOESM8_ESM.tif

Supplementary file8 Sensitivity analysis of OS at 3 years follow-up. HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival (TIF 442 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, H., Li, B. & Qin, X. The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials. Updates Surg 74, 1805–1816 (2022). https://doi.org/10.1007/s13304-022-01376-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-022-01376-5

Keywords

Search

Navigation